32 related articles for article (PubMed ID: 22661552)
1. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.
Conaghan PG; Emery P; Østergaard M; Keystone EC; Genovese MC; Hsia EC; Xu W; Rahman MU
Ann Rheum Dis; 2011 Nov; 70(11):1968-74. PubMed ID: 21784729
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation.
Baggott JE; Morgan SL
Arthritis Rheum; 2009 Aug; 60(8):2257-61. PubMed ID: 19644884
[TBL] [Abstract][Full Text] [Related]
3. Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.
Granger B; Combe B; Le Loet X; Saraux A; Guillemin F; Fautrel B
RMD Open; 2016; 2(1):e000245. PubMed ID: 27252898
[TBL] [Abstract][Full Text] [Related]
4. Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature.
Boleto G; Dramé M; Lambrecht I; Eschard JP; Salmon JH
Clin Rheumatol; 2017 Aug; 36(8):1699-1706. PubMed ID: 28669103
[TBL] [Abstract][Full Text] [Related]
5. Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.
Gwinnutt JM; Symmons DPM; MacGregor AJ; Chipping JR; Marshall T; Lunt M; Verstappen SMM
Arthritis Rheumatol; 2017 Aug; 69(8):1566-1575. PubMed ID: 28425173
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients.
Wei Y; Sun X; Hua M; Tan W; Wang F; Zhang M
Biomed Res Int; 2015; 2015():214683. PubMed ID: 26273599
[TBL] [Abstract][Full Text] [Related]
7. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?
Romão VC; Lima A; Bernardes M; Canhão H; Fonseca JE
Immunol Res; 2014 Dec; 60(2-3):289-310. PubMed ID: 25391609
[TBL] [Abstract][Full Text] [Related]
8. Folate supplementation reduces the side effects of methotrexate therapy for psoriasis.
Baran W; Batycka-Baran A; Zychowska M; Bieniek A; Szepietowski JC
Expert Opin Drug Saf; 2014 Aug; 13(8):1015-21. PubMed ID: 24972718
[TBL] [Abstract][Full Text] [Related]
9. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
Lie E; Uhlig T; van der Heijde D; Rødevand E; Kalstad S; Kaufmann C; Mikkelsen K; Kvien TK
Rheumatology (Oxford); 2012 Apr; 51(4):670-8. PubMed ID: 22157597
[TBL] [Abstract][Full Text] [Related]
11. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
12. The methotrexate therapeutic response in rheumatoid arthritis.
Ortendahl M; Holmes T; Schettler JD; Fries JF
J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
[TBL] [Abstract][Full Text] [Related]
13. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
14. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort.
Gaujoux-Viala C; Paternotte S; Combe B; Dougados M
Rheumatology (Oxford); 2012 Sep; 51(9):1648-54. PubMed ID: 22661552
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
